Michael Snyder is a Respiratory physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
701 E County Line Rd
Suite 101
Indianapolis, IN 461431070
Telephone
317-885-2334Provider last certified this registry record 9 May 2023.
Clinical trials
- Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
Sponsor: Stanford University
- Stress & Resilience Study
Sponsor: University of California, Los Angeles
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year20256 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20254 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
61.1%Corticosteroid33%Trelegy Ellipta55%Breo Ellipta20%Breztri Aerosphere12%Symbicort9%Budesonide-Formoterol Fumarate5%Part D<11 patientsbeta2-Adrenergic Agonist17%Albuterol Sulfate Hfa100%Part D≥55 patients+ 3 more classes in this area
Anti-infectives
16.8%Tetracycline-class Drug10.7%Doxycycline Hyclate100%Part D≥32 patientsMacrolide Antimicrobial6.1%Azithromycin100%Part D≥18 patientsMetabolism & gastrointestinal
14.1%Corticosteroid12.7%Prednisone100%Part D≥46 patientsProton pump inhibitor1.4%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”